Compounded Tirzepatide Injectable Vials Recalled for Sterility Assurance Issues
ProRx LLC is recalling 37 vials of compounded Tirzepatide injectable due to lack of sterility assurance. The 2 mL vials (10 mg/mL and 20 mg/mL) were distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II drug recall for compounded injectable medication with sterility assurance failures. While no illnesses or injuries have been reported, non-sterile injectables pose a serious infection risk, meeting the criteria for High severity as a risk-of-harm product.
Plain-English summary
ProRx LLC has recalled compounded Tirzepatide 2 mL injection vials at concentrations of 10 mg/mL and 20 mg/mL due to lack of assurance of sterility. The recall affects 37 vials (Lot #ProRx040924-1, BUD 10/08/2024) that were distributed nationwide in the USA.
Non-sterile injectable products carry a risk of serious infection in patients. Because the manufacturer cannot assure the sterility of these vials, patients who have received injections from the affected lot should be aware of this potential risk.
If you have received an injection from this product, contact your healthcare provider or pharmacist immediately. Do not use any remaining vials from Lot #ProRx040924-1. Healthcare providers who dispensed this product should contact patients who received injections and provide guidance on potential monitoring or follow-up care.
The recalled product
- Product
- Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01
- Manufacturer
- ProRx LLC
- Category
- Drug — Injectable / Compounded
- Hazard
- lack-of-sterility
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # ProRx040924-1
- BUD 10/08/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27